XNYS · Healthcare · Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q4 2025 | 0.21 | 0.28 | +35.24% | $6.98B | ✅ Beat | +0.49% | +0.24% | — |
| 2026-01-29 | Q3 2025 | 0.55 | 0.47 | -13.64% | $7.60B | ❌ Miss | -0.18% | +3.67% | +9.20% |
| 2025-10-30 |
| Q2 2025 |
| 0.44 |
| 0.43 |
| -2.27% |
| $7.52B |
| ❌ Miss |
| — |
| — |
| — |
| 2025-07-30 | Q1 2025 | 0.47 | 0.52 | +11.06% | $7.66B | ✅ Beat | — | — | — |
| 2025-01-30 | Q3 2024 | — | 0.44 | — | $7.51B | — | -2.26% | -0.66% | +8.32% |
| 2024-10-31 | Q2 2024 | 0.57 | 0.45 | -21.05% | $7.90B | ❌ Miss | +0.14% | -0.57% | -0.57% |
| 2024-07-31 | Q1 2024 | — | 0.56 | — | $7.75B | — | -0.22% | -0.50% | +7.28% |
| 2024-05-09 | Q4 2023 | — | 0.24 | — | $7.08B | — | -0.90% | -0.45% | +1.05% |
Showing last 8 quarters.